Spanish biotech start-up, Reveal Genomics, has announced the launch of a trial evaluating the clinical feasibility of its HER2DX genomic test designed for the diagnosis of HER2+ early-stage breast cancer.
The Barcelona-based firm announced the prospective trial (NCT06446882) in collaboration with the Boston-based research institute, the Dana-Farber Cancer Institute aimed at examining the turnaround time of the HER2DX test.
The DEFINITIVE trial will be conducted at the Brigham and Women’s Center for Advanced Molecular Diagnostics using tumour samples taken from newly diagnosed HER2+ breast cancer patients.
